Marcin Trojanowski, MD
Clinical Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Rheumatology

MD, Medical University of South Carolina
BS, College of Charleston



Marcin Trojanowski, MD is Clinical Associate Professor of Medicine Director, Rheumatology Clinic Director, Scleroderma Program Section of Rheumatology Chobanian and Avedisian School of Medicine 72 East Concord Street, 5th floor Boston, MA 02118 Marcin Trojanowski, MD is a Clinical Assistant Professor of Medicine in Rheumatology at Chobanian and Avedisian School of Medicine. He has a decade of experience in treatment of systemic sclerosis as well as a passion for medical teaching.

Prior to his arrival at BUMC, Dr. Trojanowski was the head of the Scleroderma Clinic at UAB where he was the primary referral in the region. In this role he carved out a regional role in both systemic sclerosis as well as CTD-ILD. At BUMC, he has overseen an ever expanding role within the scleroderma clinic. He also serves as the Clinical Director of the Division of Rheumatology. Dr. Trojanowski has worked on many translational and epidemiological research studies such as the Genome Research in African American Scleroderma Patients (GRASP). He has participated in directly sponsored pharmaceutical research as the principle and sub investigator of dozens of drug trials in systemic sclerosis, systemic lupus and more recently COVID 19.

In education, Dr. Trojanowski excelled at UAB as a top ten teacher in the Department of Medicine as well as a leading teacher in the Division of Rheumatology. He was a member of the Strategic Committee on Education at UAB Department of Medicine. At Boston University, Dr. Trojanowski is the director of the rheumatology musculoskeletal module for the second-year medical students and has developed a multidisciplinary problem-based learning module for first year students.

Chief Clinical Interests: Systemic Sclerosis, Connective Tissue Diseases, and Lung Disease in Connective Tissue Disease

Clinic Director
Boston University Chobanian & Avedisian School of Medicine
Medicine
Rheumatology

Director, Scleroderma Program
Boston University Chobanian & Avedisian School of Medicine
Medicine
Rheumatology

Member
Boston University
Arthritis & Autoimmune Diseases Research Center




A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
02/13/2024 - 02/13/2027 (PI)
Horizon Therapeutics


A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous
11/12/2021 - 11/11/2026 (PI)
Horizon Therapeutics


SRF-201: A Multicenter, Double-Blind, Randomized, PlaceboControlled, Phase 2b Platform Clinical Trial Evaluating the Safety and Efficacy of Investigational Products in Patients with Interstitial
09/10/2024 - 09/09/2026 (Subcontract PI)
Medpace Scleroderma Res Fdn


A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK7240/PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD)
09/20/2022 - 09/20/2025 (Subcontract PI)
PPD Development LLC Prometheus Bio, Inc


IgPro10_2001 A Randomized, Multicenter, double blind, placebo controlled, Phase 2 study to evaluate the efficacy and safety of IgPro10 (Intravenous Immunoglobulin, Privige) For the treatment of Adult
08/27/2020 - 08/27/2023 (PI)
CSL Behring LLC


A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF IFETROBAN IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
03/15/2019 - 03/14/2023 (PI)
Kadmon Corporation, LLC


Protocol # ML30172 - Scleroderma Lung Study III: Combining of anti-fibrotic effects of Pirfenidone with Mycophenolate to treat scleroderma-related interstitial lung disease
06/29/2018 - 02/28/2023 (PI)
University of California, Los Angeles


Protocol # 1199.225, An open-label extension trial to assess the long term safety of nintedanib in patients with‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD)
02/08/2018 - 02/07/2023 (PI)
Boehringer Ingelheim Pharmaceuticals, Inc.


Genome Research in African American Sclerodema Patients (GRASP)
04/05/2017 - 04/04/2022 (Subcontract PI)
The Johns Hopkins University Scleroderma Res Fdn


A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
10/18/2017 - 02/28/2022 (PI)
Corbus Pharmaceuticals Holdings, Inc.


Showing 10 of 13 results. Show All Results

CYTB323K12201: A Phase II, multi-part, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refrac
08/14/2025 - 08/13/2028 (PI)
Novartis Pharma Corp


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Lui JK, Cozzolino M, Winburn M, Trojanowski MA, LaValley MP, Bujor AM, Gopal DM, Klings ES. Risk stratifying systemic sclerosis-related pulmonary hypertension by left atrial strain. Rheumatology (Oxford). 2026 Feb 04; 65(2).View Related Profiles. PMID: 41615697; DOI: 10.1093/rheumatology/keag053;
     
  2. Kaundal U, Tsou PS, Sahu M, Huang M, Boyden SE, Woodford CM, Shriner D, Stenson E, Safran SA, Zhou Y, Talley TA, Gudapati K, Zhang X, Kunishita Y, Wang J, Shah AA, Mayes MD, Doumatey AP, Bentley AR, Domsic R, Medsger TA, Ramos PS, Silver RM, Steen V, Varga J, Hsu V, Saketkoo LA, Schiopu E, Gordon JK, Criswell LA, Gladue H, Derk C, Bernstein EJ, Bridges SL, Shanmugam V, Chung L, Kafaja S, Jan R, Trojanowski M, Goldberg A, Korman BD, Mullikin J, Thomas JW, Dell'Orso S, Randazzo D, Adeyemo A, Remmers EF, Schwartzberg PL, Aksentijevich I, Rotimi C, Wigley FM, Wang RA, Boin F, Khanna D, Lafyatis R, Kastner DL, Gourh P. Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis. Ann Rheum Dis. 2026 Feb 04.View Related Profiles. PMID: 41644364
     
  3. Lui JK, El-Adili F, Cozzolino M, Winburn M, Trojanowski MA, Gopal DM, LaValley MP, Klings ES, Bujor AM. A multi-biomarker approach to risk stratification and detection of early cardiac disease in systemic sclerosis. PLoS One. 2025; 20(7):e0328734.View Related Profiles. PMID: 40743121; PMCID: PMC12312888; DOI: 10.1371/journal.pone.0328734;
     
  4. Dinc MT, El-Adili F, Lui JK, Kripesh S, York M, Trojanowski M, Ligresti G, Lafyatis R, Trojanowska M, Bujor AM. Transcriptomic profiling of scleroderma monocytes reveals links with cardiovascular complications, implicating Notch and interferon pathways. J Scleroderma Relat Disord. 2025 Jul 25; 23971983251356123.View Related Profiles. PMID: 40735732; PMCID: PMC12301231; DOI: 10.1177/23971983251356123;
     
  5. Chung L, Silver RM, Steen V, Furst DE, Castelino FV, Trojanowski M, Spiera R, Domsic R, Rodriguez-Pla A, Katsumoto TR, Goulaouic H, Wang H, Espinasse M, El-Chemaly S, Wang R. Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study. Rheumatology (Oxford). 2025 Jul 01; 64(7):4299-4308. PMID: 40088930; PMCID: PMC12212915; DOI: 10.1093/rheumatology/keaf062;
     
  6. Lui JK, Cozzolino M, Winburn M, Trojanowski MA, Soylemez Wiener R, LaValley MP, Bujor AM, Gopal DM, Klings ES. Clustering regional patterns of left ventricular longitudinal strain in systemic sclerosis-related pulmonary hypertension. Int J Cardiol. 2025 Feb 15; 421:132891.View Related Profiles. PMID: 39662748; PMCID: PMC11747944; DOI: 10.1016/j.ijcard.2024.132891;
     
  7. Yamashita T, Kaplan U, Chakraborty A, Marden G, Gritli S, Roh D, Bujor A, Trojanowski M, Ligresti G, Browning JL, Trojanowska M. ERG Regulates Lymphatic Vessel Specification Genes and Its Deficiency Impairs Wound Healing-Associated Lymphangiogenesis. Arthritis Rheumatol. 2024 Nov; 76(11):1645-1657.View Related Profiles. PMID: 38965683; PMCID: PMC11521767; DOI: 10.1002/art.42944;
     
  8. Lui JK, Sangani RA, Gillmeyer KR, Vakhshoorzadeh J, Trojanowski MA, Bujor AM, Gopal DM, Wiener RS, LaValley MP, Klings ES. Correction to: Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension. Cardiovasc Drugs Ther. 2024 Jun; 38(3):657.View Related Profiles. PMID: 36662449; PMCID: PMC11528702; DOI: 10.1007/s10557-023-07431-6;
     
  9. Cegla P, Currie GM, Cholewinski W, Bryl M, Trojanowski M, Matuszewski K, Piotrowski T, Czepczynski R. [18F]fluorodeoxyglucose positron emission tomography/computed tomography in combination with clinical data in predicting overall survival in non-small-cell lung cancer patients: A retrospective study. Radiography (Lond). 2024 May; 30(3):971-977. PMID: 38663216
     
  10. Lui JK, Cozzolino M, Winburn M, Trojanowski MA, Wiener RS, LaValley MP, Bujor AM, Gopal DM, Klings ES. Role of Left Ventricular Dysfunction in Systemic Sclerosis-Related Pulmonary Hypertension. Chest. 2024 Jun; 165(6):1505-1517.View Related Profiles. PMID: 38128607; PMCID: PMC11177103; DOI: 10.1016/j.chest.2023.12.018;
     
Showing 10 of 22 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 22 publications over 9 distinct years, with a maximum of 6 publications in 2023

YearPublications
20171
20181
20191
20202
20222
20236
20244
20253
20262

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Systemic Lupus
Rheumatology
Contact for Mentoring:

72 E. Concord St Evans Building
Boston MA 02118
Google Map


Trojanowski's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department